Virtu Financial LLC Takes $824,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Virtu Financial LLC acquired a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 19,644 shares of the biopharmaceutical company’s stock, valued at approximately $824,000.

A number of other large investors also recently modified their holdings of CLDX. Vanguard Group Inc. lifted its stake in shares of Celldex Therapeutics by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,618,504 shares of the biopharmaceutical company’s stock valued at $72,061,000 after buying an additional 20,688 shares in the last quarter. Panoramic Investment Advisors LLC purchased a new position in shares of Celldex Therapeutics during the 4th quarter valued at $258,000. Arizona State Retirement System lifted its stake in shares of Celldex Therapeutics by 20.3% during the 4th quarter. Arizona State Retirement System now owns 13,758 shares of the biopharmaceutical company’s stock valued at $546,000 after buying an additional 2,322 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in shares of Celldex Therapeutics during the 4th quarter valued at $994,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Celldex Therapeutics by 3.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,258 shares of the biopharmaceutical company’s stock valued at $1,041,000 after buying an additional 962 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Tuesday. Stifel Nicolaus assumed coverage on shares of Celldex Therapeutics in a research note on Tuesday, June 18th. They set a “buy” rating and a $58.00 target price on the stock. Wolfe Research assumed coverage on shares of Celldex Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research note on Tuesday. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.17.

Insider Activity

In other news, SVP Margo Heath-Chiozzi sold 38,719 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $34.07, for a total transaction of $1,319,156.33. Following the sale, the senior vice president now directly owns 7,094 shares in the company, valued at approximately $241,692.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, SVP Diane C. Young sold 45,000 shares of the company’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $35.26, for a total transaction of $1,586,700.00. Following the sale, the senior vice president now directly owns 2,115 shares in the company, valued at approximately $74,574.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Margo Heath-Chiozzi sold 38,719 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $34.07, for a total transaction of $1,319,156.33. Following the sale, the senior vice president now owns 7,094 shares in the company, valued at $241,692.58. The disclosure for this sale can be found here. In the last three months, insiders have sold 266,332 shares of company stock worth $9,155,821. 3.80% of the stock is currently owned by corporate insiders.

Celldex Therapeutics Trading Down 7.4 %

Shares of CLDX stock opened at $34.78 on Friday. Celldex Therapeutics, Inc. has a 52 week low of $22.11 and a 52 week high of $53.18. The company’s fifty day simple moving average is $36.74 and its two-hundred day simple moving average is $39.10.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.11. The firm had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $1.30 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. On average, sell-side analysts forecast that Celldex Therapeutics, Inc. will post -2.39 EPS for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.